Outlook Therapeutics updates status of Lytenava (bevacizumabvikg) NORSE 1

Article

Patient enrollment for NORSE 2 completed

Outlook Therapeutics remains on track to report topline results in August from NORSE 1, the company’s first registration clinical trial evaluating ONS-5010. Clinical experience and initial safety and efficacy data will be unveiled.

ONS-5010 is an investigational ophthalmic formulation of bevacizumab to treat wet age-related macular degeneration (AMD). If approved by the U.S. Food and Drug Administration (FDA), ONS-5010 will be the first FDA-approved ophthalmic formulation of bevacizumab for use in multiple retinal indications including wet AMD, diabetic macular edema (DME) and branch retinal vein occlusion (BRVO), according to the company.

Related: CooperVision reveals virtual exhibit booth

ONS-5010 is a full-length, humanized anti-vascular endothelial growth factor (VEGF) recombinant monoclonal antibody (mAb) that works by blocking the growth of abnormal blood vessels secreted in the eyes of wet AMD patients. The drug is administered as an intravitreal injection, dosed monthly.

“The next key element in our streamlined regulatory pathway for ONS-5010 is our ongoing pivotal clinical trial, NORSE 2, which remains on track to complete enrollment within the next two months, with topline results expected in the third calendar quarter of 2021,” said Lawrence Kenyon, President of Outlook Therapeutics, in a statement.

Related: Study shows cryopreserved amniotic membranes improve SJS and TEN

“Additionally, we are preparing to initiate the NORSE 3 open-label study, which is meant to ensure enough patients have been exposed to ONS-5010 to meet the requirements for our planned BLA submission next year. We expect to commence NORSE 3 in the fourth calendar quarter of 2020.”

If approved, Outlook Therapeutics plans to commercialize ONS-5010 in the United States, Europe, Japan, and other markets. Additionally, the company expects to file ONS-5010 with the FDA as a new biologics license application (BLA) under the Public Health Service Act 351(a) regulatory pathway.

Patient enrollment for the NORSE 2 clinical trial for ONS-5010 has been completed.

Related: Demodox blepharitis treatment shows positive results, says Tarsus

Recent Videos
Cecilia Koetting, OD, FAAO, DipABO, cited data from a recent student that found that presbyopia treatment with 0.4% pilocarpine led to up to 86% of patients achieving 20/40 or better.
Kerry Giedd, OD, MS, FAAO, was 1 of 20 investigators around the country for a study evaluating the daily disposable contact lens.
According to A. Paul Chous, MA, OD, FAAO, optometrists have an important opportunity to educate patients in their chairs about diabetes.
David Geffen, OD, FAAO, gave a poster presentation titled "Revolutionizing Comfort: Unveiling the Potential of Perfluorohexyloctane Eyedrops for Contact Lens Wearers" at this year's Academy meeting.
Jessica Steen, OD, FAAO, Dipl-ABO, discussed ophthalmic considerations for patients undergoing treatment with antibody drug conjugates for gynecologic cancers at this year's conference.
A. Paul Chous, MA, OD, FAAO, details a presentation on this year's updates on diabetes given at this year's Academy meeting
Sherrol Reynolds, OD, FAAO, said that multimodel imaging has been a game changer in assessing the choroidal function and structural changes in various disease conditions.
Susan Gromacki, OD, FAAO, FSLS, provides key takeaways from this year's American Academy of Optometry symposium genetics and the cornea.
Roya Attar gives an overview of her presentation, "Decoding the Retina: The Value of Genetic Testing In Inherited Disorders," presented with Mohammad Rafieetary, OD, FAAO, FORS, ABO, ABCMO.
Ian Ben Gaddie, OD, FAAO, outlines key findings from a recent study evaluating lotilaner in patients with Demodex blepharitis and meibomian gland dysfunction.
© 2024 MJH Life Sciences

All rights reserved.